Guilherme Perini, Hematologist at Hospital Israelita Albert Einstein in São Paulo, shared a post on X:

“First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

Tim Fenske and ECOG-ACRIN EA4151 investigators show that, for patients achieving MRD negativity after modern induction in MCL does not benefit from ASCT.

MRD was done by ClonoSeq, not avaliable in Latam.

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Authors: Timothy S. Fenske, Xin Victoria Wang, Brian G. Till, Kristie A. Blum, Matthew Lunning, Hillard M. Lazarus, Paul A.S. Fishkin, Lale Kostakoglu Shields, David W. Scott, Ann S. LaCasce, Patrick B. Johnston, Amanda F. Cashen, Leslie L. Popplewell, Robert M. Dean, Nausheen Ahmed, , Nirav N. Shah, Nina D. Wagner-Johnston, Boyu Hu, Bhagirathbhai R. Dholaria, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl.

First hit on Autologous Stem Cell Transplantation in Mantle cell lymphoma

As data from Grupo GELL has shown, less than 40 percent of eligible patients in LatAm go to ASCT in MCL.

ClonoSeq is waycheaper than ASCT, and could help, in $-restricted countries, select patients who really benefit from ASCT…

And that was not the biggest hit in ASCT for MCL…”